NeoVanc

NeoVanc

Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months

Funded by the European Commission’s FP7 programme, NeoVanc involves 12 European partners and is coordinated by PENTA.

The aim is to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age and subsequently conduct a randomised clinical trial with PK/PD targets as the primary outcome.

Go to website

 

 

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041  flag_yellow_high